MedTrace Logo

Ondanstron Weekly vs Every 3 Weeks for Prevention of Nausea and Vomiting Induced by Chemotherapy Combined With PD-1 Blockade

NCT06080880 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 98

Last updated 2024-02-29

No results posted yet for this study

Summary

The aim of this randomized study is to compare the efficacy and safety of ondanstron weekly with every 3 weeks for the prevention of nausea and vomiting induced by chemotherapy combined with PD-1 blockade.

Conditions

  • Nausea With Vomiting Chemotherapy-Induced

Interventions

DRUG

Ondansetron every 3 weeks

Ondansetron, Po, 24mg/d, 3 days' application every 3 weeks

DRUG

Aprepitant

aprepitant, Po, 125mg/d, 1day' application every 3 weeks

DRUG

Dexamethasone

dexamethasone, iv, 10mg/d, 1day' application every 3 weeks

DRUG

Ondansetron weekly

Ondansetron, Po, 24mg/d, 3 days' application weekly

Sponsors & Collaborators

  • Hubei Cancer Hospital

    lead OTHER

Principal Investigators

  • Guang Han, MD · Hubei Cancer Hospital, Wuhan, HuBei, China, 430079

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-01
Primary Completion
2025-11-30
Completion
2027-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06080880 on ClinicalTrials.gov